Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review.
Autor: | Mehta N; Tribhuvan University Teaching Hospital Maharajgunj Nepal., Shah S; Division of Research Affairs, Larkins Community Hospital South Miami Florida USA.; Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University Maharajgunj Nepal., Paudel K; Nepal Health Frontiers, Tokha-5 Kathmandu Nepal., Chamlagain R; Tribhuvan University Teaching Hospital Maharajgunj Nepal., Chhetri S; Department of Nephrology and Transplantation Medicine, Institute of Medicine Tribhuvan University Maharajgunj Nepal. |
---|---|
Jazyk: | angličtina |
Zdroj: | Health science reports [Health Sci Rep] 2022 Jun 16; Vol. 5 (4), pp. e700. Date of Electronic Publication: 2022 Jun 16 (Print Publication: 2022). |
DOI: | 10.1002/hsr2.700 |
Abstrakt: | Background and Aims: Patients on maintenance dialysis are a high-risk, immune-compromised population with 15%-25% coronavirus disease (COVID-19) mortality rate that has been underrepresented in COVID-19 vaccination clinical trials. The aim of study was to review of those studies to determine the safety and efficacy of the COVID-19 vaccination in chronic kidney disease (CKD) patients receiving maintenance hemodialysis systematically. Methods: The effectiveness was assessed by looking at the humoral and cellular responses. The humoral response is defined as de novo IgG- or IgA-anti-SpikeS1 antibody positivity. The establishment of de novo T-cell immunity after immunization was used to measure cellular response. Adverse results were also reported of the included studies to analyze the safety of COVID-19 vaccines. Eight previous works were included in our study. Results: Two doses of COVID-19 vaccines were shown to be effective with seroconversion rate of humoral response ranging from 81% to 97% among eight studies. The T-cell response was shown 67% and 100% in two studies. COVID-19 vaccines did not have notable adverse events and hence can be considered safe. Conclusion: Although a single dosage has not shown to improve humoral immune response in most hemodialysis trials, a double dose has been reported to improve seroconversion rate and humoral immune response. Further research are required to observe if hemodialysis patients generate effective T-cell responses. Competing Interests: The authors declare no conflict of interest. (© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.) |
Databáze: | MEDLINE |
Externí odkaz: |